- Biotransformation of a crizotinib intermediate using a mutant alcohol dehydrogenase of Lactobacillus kefir coupled with glucose dehydrogenase
-
(S)-1-(2, 6-dichloro-3-fluorophenyl) ethanol, the key chiral intermediate of crizotinib, was prepared from 1-(2, 6-dichloro-3-fluorophenyl) ethanone using the alcohol dehydrogenases from Lactobacillus kefir (ADH-LK) with a tetrad mutant (ADH-LKM, F147L/Y1
- Zong, Chuhong,Zhang, Xu,Yang, Fei,Zhou, Yafeng,Chen, Nan,Yang, Zuisu,Ding, Guofang,Yu, Fangmiao,Tang, Yunping
-
-
Read Online
- Abiotic reduction of ketones with silanes catalysed by carbonic anhydrase through an enzymatic zinc hydride
-
Enzymatic reactions through mononuclear metal hydrides are unknown in nature, despite the prevalence of such intermediates in the reactions of synthetic transition-metal catalysts. If metalloenzymes could react through abiotic intermediates like these, then the scope of enzyme-catalysed reactions would expand. Here we show that zinc-containing carbonic anhydrase enzymes catalyse hydride transfers from silanes to ketones with high enantioselectivity. We report mechanistic data providing strong evidence that the process involves a mononuclear zinc hydride. This work shows that abiotic silanes can act as reducing equivalents in an enzyme-catalysed process and that monomeric hydrides of electropositive metals, which are typically unstable in protic environments, can be catalytic intermediates in enzymatic processes. Overall, this work bridges a gap between the types of transformation in molecular catalysis and biocatalysis. [Figure not available: see fulltext.]
- Ji, Pengfei,Park, Jeeyoung,Gu, Yang,Clark, Douglas S.,Hartwig, John F.
-
p. 312 - 318
(2021/02/26)
-
- Preparation method of deuterated crizotinib and derivatives thereof
-
The invention relates to a preparation method of deuterated crizotinib and derivatives thereof, and belongs to the technical field of synthesis of medical compounds. Four deuterated crizotinib with different configurations are synthesized, the influence of the deuterated position and different chirality of the deuterated crizotinib on the biological activity and the drug metabolism property of thecrizotinib is investigated, and the result shows that the deuterated crizotinib and the crizotinib have similar anti-cancer activity. Compared with a deuterated crizotinib raceme and crizotinib, thedeuterated crizotinib has certain physicochemical property advantages, has good anticancer application prospects, and provides a new compound for synthesis of novel antitumor drugs. The resolution ofthe racemate phenylethanol derivative is a key step for synthesizing the deuterated crizotinib, the ee value of the racemate phenylethanol derivative directly influences the ee value of a final product, and the resolution method has the characteristics of easiness in operation, low cost and the like.
- -
-
Paragraph 0068-0070; 0079; 0081
(2020/12/31)
-
- Manganese-Catalyzed Enantioselective Hydrogenation of Simple Ketones Using an Imidazole-Based Chiral PNN Tridentate Ligand
-
A series of Mn(I) catalysts containing imidazole-based chiral PNN tridentate ligands with controllable 'side arm' groups have been established, enabling the inexpensive base-promoted asymmetric hydrogenation of simple ketones with outstanding activities (up to 8200 TON) and good enantioselectivities (up to 88.5percent ee). This protocol features wide substrate scope and functional group tolerance, thereby providing easy access to a key intermediate of crizotinib.
- Chen, Jiachen,Hou, Huacui,Ling, Fei,Nian, Sanfei,Wu, Feifei,Xu, Min,Yi, Xiao,Zhong, Weihui
-
supporting information
p. 285 - 289
(2020/02/18)
-
- Synthesis method of (S)-1-(2, 6-dichloro-3-fluorophenyl)-ethanol
-
The invention relates to a synthesis method of (S)-1-(2, 6-dichloro-3-fluorophenyl)-ethanol. The synthesis method comprises the following steps: mixing 2, 6-dichloro-3- fluoroacetophenone, a chiral catalyst, alkali and a solvent, and carrying out a reacti
- -
-
Page/Page column 11-14
(2020/09/09)
-
- Chiral ferrocene phosphine-nitrogen-nitrogen tridentate ligand as well as preparation method and application thereof
-
The invention discloses a chiral ferrocene phosphine-nitrogen-nitrogen tridentate ligand as well as a preparation method and an application thereof. The general structural formula of the chiral ferrocene phosphine-nitrogen-nitrogen tridentate ligand is shown in formula (I) or formula (II), wherein R1 and R2 are independently selected from C1-C6 alkyl, C3-C6 cycloalkyl, aryl or heterocyclic aryl respectively; R3 is aryl, heterocyclic aryl or C1-C6 alkyl, and R4 is hydrogen, C1-C6 alkyl, aryl or heterocyclic aryl; the general structural formula in the formula (I) and the formula (II) contains animidazole group or a substituted benzimidazole group respectively; one or more substituent groups exist on a benzene ring of the substituted benzimidazole group, and each substituent group is independently selected from H or C1-C4 alkyl. The chiral ferrocene phosphine-nitrogen-nitrogen tridentate ligand has the advantages that the tridentate ligand is convenient to synthesize, exists in the air stably and can be coordinated with cheap metal to prepare a cheap metal catalyst, and the cheap metal catalyst is well applied to asymmetric hydrogenation reactions of ketone.
- -
-
Paragraph 0079-0082; 0084
(2019/10/01)
-
- Towards practical earth abundant reduction catalysis: Design of improved catalysts for manganese catalysed hydrogenation
-
Manganese catalysts derived from tridentate P,N,N ligands can be activated easily using weak bases for both ketone and ester hydrogenations. Kinetic studies indicate the ketone hydrogenations are 0th order in acetophenone, positive order in hydrogen and 1st order in the catalyst. This implies that the rate determining step of the reaction was the activation of hydrogen. New ligand systems with varying donor strength were studied and it was possible to make the hydrogen activation significantly more efficient; a catalyst displaying around a 3-fold increase in initial turn-over frequencies for the hydrogenation of acetophenone relative to the parent system was discovered as a result of these kinetic investigations. Ester hydrogenations and ketone transfer hydrogenation (isopropanol as reductant) are first order for both the substrate and catalysts. Kinetic studies also gained insight into catalyst stability and identified a working range in which the catalyst is stable throughout the catalytic reaction (and a larger working range where high yields can still be achieved). The new more active catalyst, combining an electron-rich phosphine with an electron-rich pyridine is capable of hydrogenating acetophenone using as little as 0.01 mol% catalyst at 65 °C. In all, protocols for reduction of 21 ketones and 15 esters are described.
- Widegren, Magnus B.,Clarke, Matthew L.
-
p. 6047 - 6058
(2019/11/14)
-
- MANUFACTURING METHOD OF OPTICAL ACTIVE SECONDARY ALCOHOL
-
PROBLEM TO BE SOLVED: To provide a method for manufacturing optical active secondary alcohol with high optical purity by hydrogenating a substrate carbonyl compound using a ruthenium complex with a specific optical active diphosphine compound and an amine compound of which synthesis is easy as ligands as a catalyst. SOLUTION: The manufacturing method of optical active secondary alcohol including reacting a substrate carbonyl compound (excluding 3-quinuclidinone, a 3-quinuclidinone derivative having a substituent, and ketone having an aromatic hydrocarbon group and a heterocycle) with hydrogen and/or a hydrogen-donating compound in a presence of a ruthenium complex selected from a compound represented by the following general formula (1) RuXYAB (1) [X and Y are same or different, represent a hydrogen atom or an anionic group, A represents optical active diphosphine represented by the general formula (2), and B represents an amine compound represented by the following general formula (3)]. SELECTED DRAWING: None COPYRIGHT: (C)2019,JPO&INPIT
- -
-
Paragraph 0113-0117
(2019/03/20)
-
- Method for preparing crizotinib intermediate by using immobilized chiral catalyst
-
The invention relates to a method for preparing a crizotinib intermediate by using an immobilized chiral catalyst. The method can effectively solve the problems that according to existing methods, thematerial consumption is high, the cost is high and cata
- -
-
Paragraph 0013-0020
(2019/10/01)
-
- Asymmetric Hydrogenation of Polysubstituted Aromatic Ketones Catalyzed by the DIPSkewphos/PICA Derivative–Ruthenium(II) Complexes
-
The DIPSkewphos/PICA derivative-Ru(II) complexes catalyzed asymmetric hydrogenation of significantly sterically hindered 2’,3’,4’,5’,6’-pentamethylacetophenone, which was not reduced with NaBH4 at 25 °C, with a substrate-to-catalyst molar ratio
- Utsumi, Noriyuki,Arai, Noriyoshi,Kawaguchi, Kei,Katayama, Takeaki,Yasuda, Toshihisa,Murata, Kunihiko,Ohkuma, Takeshi
-
p. 3955 - 3959
(2018/08/01)
-
- A Highly Active Manganese Catalyst for Enantioselective Ketone and Ester Hydrogenation
-
A new hydrogenation catalyst based on a manganese complex of a chiral P,N,N ligand has been found to be especially active for the hydrogenation of esters down to 0.1 mol % catalyst loading, and gives up to 97 % ee in the hydrogenation of pro-chiral deactivated ketones at 30–50 °C.
- Widegren, Magnus B.,Harkness, Gavin J.,Slawin, Alexandra M. Z.,Cordes, David B.,Clarke, Matthew L.
-
supporting information
p. 5825 - 5828
(2017/05/12)
-
- Crizotinib intermediate, preparation method and crizotinib preparation method
-
The invention relates to a crizotinib intermediate, a preparation method and a crizotinib preparation method, in particular to an intermediate of crizotinib which has the structure of a formula (CZT-5) as shown in the description and the structure of a formula (CZT-9) as shown in the description, a preparation method of the intermediate and a preparation method of a crizotinib with the structure of a formula (CZT-11). The method provided by the invention has the characteristics of short route, high yield, easiness in acquisition of raw materials, high reaction selectivity and the like, chiral resolution is not required in a synthetic process, the utilization rate of the raw materials is increased, the path costs are low, and therefore, the method can meet requirements of large-scale industrial production.
- -
-
Paragraph 0047; 0048
(2017/08/28)
-
- Preparation method of crizotinib intermediate
-
The invention discloses a synthetic method of anti-tumor molecular targeted drug crizotinib, belongs to the field of pharmaceuticals, and relates to a synthetic method of a crizotinib intermediate. The method comprises two reduction processes: a bromination reaction process comprises the following reaction steps: a reduction process I: carrying out reduction reaction on a (R)-3-[1-(2,6-dichloro-3-fluorophenyl)ethoxyl]-2-nitropyridine compound and sodium dithionate under a mechanical chemical condition to generate (R)-3-[1-(2,6-dichloro-3-fluorophenyl)ethoxyl]-2-aminopyridine; a reduction process II: dissolving the (R)-3-[1-(2,6-dichloro-3-fluorophenyl)ethoxyl]-2-nitropyridine compound into an organic solvent, carrying out catalytic hydrogenation and reduction treatment to generate (R)-3-[1-(2,6-dichloro-3-fluorophenyl)ethoxyl]-2-aminopyridine; the bromination reaction process comprises a step of carrying out reaction between the compound and potassium hydrogen persulfate as well as bromate to obtain the crizotinib intermediate. The process is low in cost, the raw materials are easy to purchase, the operation is simple, convenient and safe, and the yield is high; moreover, the process is suitable for large-scale production.
- -
-
Paragraph 0021
(2017/12/29)
-
- CRIZOTINIB FOR USE IN THE TREATMENT OF CANCER
-
The present invention relates to the use of ROS kinase inhibitors for treating abnormal cell growth in mammals. In particular, the invention provides methods of treating mammals suffering from cancer mediated by at least one genetically altered ROS. In particular, the invention provides methods of treating mammals suffering from cancer mediated by at least one genetically altered ROS by administration of crizotinib.
- -
-
-
- Preparation method of crizotinib intermediate (S)-1-(2,6-dichloro-3-fluorophenyl) ethanol
-
The invention belongs to the technical field of organic chemistry, also belongs to the technical field of medicinal chemistry, and in particular to a preparation method of a crizotinib intermediate (S)-1-(2,6-dichloro-3-fluorophenyl) ethanol. The method u
- -
-
Paragraph 0034; 0035
(2016/10/07)
-
- Preferential crystallization preparation method of chiral alpha-phenylethyl alcohol
-
The invention discloses a method for preparing chiral alpha-phenylethyl alcohol. The method is a preferential crystallization method implemented by taking petroleum ether as a solved, is simple and convenient to operate, is high in product yield and purit
- -
-
-
- An anti-tumor molecule targeting drug [...] process for the synthesis of
-
The invention provides a synthetic process method for a novel antineoplastic molecular targeted drug of crizotinib, and relates to the resolution process optimization of chiral isomers of a crizotinib precursor and the recycling of by-products. The method adopts a catalyzing resolution method that Boc-L-proline, namely, N-(tert-butoxycarbonyl)-L-proline) is combined with a catalyst of p-toluenesulfonic acid and a condensating agent of 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride to split 1-(2,6-dichloro-3-fluorophenyl)ethanol racemate into S-type alcohol and R-type alcohol, and a resolution by-product mixture is subjected to hydrolysis and configuration transition to obtain the (S)-1-(2,6-dichloro-3-fluorophenyl)ethanol; the total yield is improved to 76% from 30%, the time is shortened, pollution is reduced, and application to industrialized production is easy.
- -
-
-
- PROCESS FOR PRODUCING OPTICALLY ACTIVE SECONDARY ALCOHOL
-
[Object] The object of this invention is to provide a method for producing an optically active secondary alcohol at a high optical purity by hydrogenating a substrate carbonyl compound at a high efficiency using as a catalyst a ruthenium complex bearing as a ligand certain optically active diphosphine compound and a readily synthesized amine compound. [Solution] The method of producing an optically active secondary alcohol according to the present invention is characterized in that a substrate carbonyl compound (provided that 3-quinuclidinone, 3-quinuclidinone derivative having a substituent, and a ketone having an aromatic hydrocarbon group and a heterocycle are excluded) is reacted with hydrogen and/or a hydrogen donating compound in the presence of a ruthenium complex selected from the compounds expressed by following general formula (1) RuXYAB (1) [in the general formula (1), X and Y are the same or different from each other and denote a hydrogen atom or an anionic group, A denotes an optically active diphosphine expressed by the general formula (2), B denotes an amine compound expressed by following general formula (3)].
- -
-
Paragraph 0169
(2015/02/19)
-
- PRODUCTION METHOD OF OPTICALLY ACTIVE SECONDARY ALCOHOL
-
PROBLEM TO BE SOLVED: To provide a chemical catalytic method allowing efficient production of a corresponding optically active secondary alcohol from an aromatic ketone having a substituent at each of two β-positions in an aromatic ring to the carbonyl site, so that both enantiomers can be separately made. SOLUTION: A production method of optically active secondary alcohol is characterized by reacting a ketone compound such as acetophenone derivatives with hydrogen in the presence of a ruthenium complex catalyst having an optically active diphosphine ligand. COPYRIGHT: (C)2015,JPO&INPIT
- -
-
Paragraph 0132
(2016/11/14)
-
- Inhibitors of nedd8-activating enzyme
-
The invention relates to an administration unit comprising crystalline form I of {(1 S,2S,4R)-4-[(6-{[(1R,2S)-5-chloro-2methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate (I-216) hydrochloride salt and to a packaging comprising the administration unit according to the invention.
- -
-
-
- A novel approach for the synthesis of Crizotinib through the key chiral alcohol intermediate by asymmetric hydrogenation using highly active Ir-Spiro-PAP catalyst
-
A novel approach for the synthesis of Crizotinib (1) is described. In addition, new efficient procedures have been developed for the preparation of (S)-1-(2,6-dichloro-3-fluorophenyl)ethanol (2) and tert-butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl) piperidine-1-carboxylate (4), the key intermediates required for the synthesis of Crizotinib.
- Qian, Jian-Qiang,Yan, Pu-Cha,Che, Da-Qing,Zhou, Qi-Lin,Li, Yuan-Qiang
-
p. 1528 - 1531
(2014/03/21)
-
- CRIZOTINIB FOR USE IN THE TREATMENT OF CANCER
-
The present invention relates to the use of ROS kinase inhibitors for treating abnormal cell growth in mammals. In particular, the invention provides methods of treating mammals suffering from cancer mediated by at least one genetically altered ROS. In particular, the invention provides methods of treating mammals suffering from cancer mediated by at least one genetically altered ROS by administration of crizotinib.
- -
-
-
- SPIROCYCLIC MOLECULES AS PROTEIN KINASE INHIBITORS
-
The present invention relates to spirocyclic compounds of formula I, namely spirocyclic (1H-pyrazol-4-yl)-3-(1-(2,6-dichloro-3-fiuorophenyl) ethoxy)pyridin-2-amines having protein kinase inhibitory activity, and methods of synthesizing and using such compounds. Preferred compounds are c-Met and/or ALK inhibitors useful for the treatment of abnormal cell growth, such as cancers
- -
-
Paragraph 00193-00194
(2013/03/26)
-
- Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors
-
A series of 2-amino-N-benzylpyridine-3-carboxnamides, 2-amino-N- benzylpyridine-3-sulfonamides and 2-amino-3-benzylthiopyridines against c-Met were designed by means of bioisosteric replacement and docking analysis. Optimization of the 2-amino-3-benzylthiopyridine scaffold led to the identification of compound (R)-10b displaying c-Met inhibition with an IC 50 up to 7.7 nM. In the cytotoxic evaluation, compound (R)-10b effectively inhibited the proliferation of c-Met addictive human cancer cell lines (IC50 from 0.19 to 0.71 μM) and c-Met activation-mediated cell metastasis. At a dose of 100 mg/Kg, (R)-10b evidently inhibited tumor growth (45%) in NIH-3T3/TPR-Met xenograft model. Of note, (R)-10b could overcome c-Met-activation mediated gefitinib-resistance, which indicated its potential use for drug combination. Taken together, 2-amino-3-benzylthiopyridine scaffold was first disclosed and exhibited promising pharmacological profiles against c-Met, which left room for further exploration.
- Zhang, Dengyou,Zhang, Xiaowei,Ai, Jing,Zhai, Yun,Liang, Zhongjie,Wang, Ying,Chen, Yi,Li, Chunpu,Zhao, Fei,Jiang, Hualiang,Geng, Meiyu,Luo, Cheng,Liu, Hong
-
p. 6804 - 6820
(2013/10/22)
-
- SUBSTITUTED PYRIDAZINE CARBOXAMIDE COMPOUNDS AS KINASE INHIBITOR COMPOUNDS
-
The new pyridazine derivatives have unexpected drug properties as inhibitors of protein kinases especially against c-Met and are useful in treating disorders related to abnormal protein kinase activities such as cancer.
- -
-
-
- SUBSTITUTED PYRIDAZINE CARBOXAMIDE COMPOUNDS
-
The new pyridazine derivatives have unexpected drug properties as inhibitors of protein kinases especially against ALK and are useful in treating disorders related to abnormal protein kinase activities such as cancer, neurological and psychiatric diseases
- -
-
-
- Biotransformation-mediated synthesis of (1S)-1-(2,6-dichloro-3- fluorophenyl)ethanol in enantiomerically pure form
-
An efficient four-step biotransformation-mediated synthesis of (1S)-1-(2,6-dichloro-3-fluorophenyl)ethanol in enantiomerically pure form is described. This compound is a key intermediate required for the preparation of PF-2341066, a potent inhibitor of c-
- Martinez, Carlos A.,Keller, Eric,Meijer, Renzo,Metselaar, Gerard,Kruithof, Gerlof,Moore, Curtis,Kung, Pei-Pei
-
experimental part
p. 2408 - 2412
(2010/12/25)
-
- Polymorphs of a C-Met/Hgfr Inhibitor
-
This invention relates to polymorphs of (R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to compositions including such salts and polymorphs, and to methods of using such compositions in the treatment of abnormal cell growth in mammals, especially humans.
- -
-
Page/Page column 4-5
(2009/01/20)
-
- PYRAZOLE-SUBSTITUTED AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS
-
Compounds of formula (1) are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.
- -
-
Page/Page column 59
(2010/10/20)
-
- AMINOHETEROARYL COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS
-
Aminoheteroaryl compounds are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.
- -
-
Page/Page column 50-51
(2010/10/20)
-